NCT06613269RecruitingPhase 2
68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
Effect of 68Ga-NY104 and 18F-FDG PET/CT Guided Radiation Therapy Combined with Systemic Treatment in Patients with Clear Cell Renal Cell Carcinoma.
Source: ClinicalTrials.gov · Last updated 27 Sept 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Radiation therapy (RT) is an effective treatment for patients with advanced-stage clear cell renal cell carcinoma (ccRCC). Current evidence has shown promising outcomes combining radiation therapy and standard systemic therapy in patients with metastatic/recurrent ccRCC. CAIX is a highly sensitive and specific biomarker expressed on ccRCC and in previous studies the investigators have shown excellent diagnostic efficacy of 68Ga-NY104, a CAIX-targeted PET tracer, in patients with metastatic ccRCC. In this study, the investigators aim to investigate the effect of 68Ga-NY104, and 18F-FDG PET/CT guided RT combining standard systemic therapy in patients with metastatic ccRCC.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 23 Sept 2024
- Start date
- 27 Mar 2024
- Primary completion date
- Sept 2026
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Kidney cancer
- NCT number
- NCT06613269
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- From 27 Mar 2024 to the primary completion date, Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other malignant tumors that are not controlled within 5 years, except for non-metastatic low-risk prostate cancer.
- Active infection.
Other
- Brain metastasis/carcinomatous meningitis
- Pregnant or breastfeeding.
Who the study is looking for
- Age ≥ 18 years old
- Histologically or cytologically confirmed clear cell renal cell carcinoma
- Eligible for radiation therapy: no more than 10 lesions in total
- Expected survival: over 3 months
- ECOG: 0 or 1
- Sufficient organ function
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.